The KEYNOTE-010 study demonstrated the durable response of pembrolizumab in patients with high tumor PD-L1 expression, leading to subsequent KEYNOTE-024 trial that compared pembrolizumab monotherapy with platinum-based chemotherapy specifically in patients with high tumor PD-L1 expression (2, 42). The gene discussed is CD274; the disease is neoplasm.